SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2021 / Cilt: 51 - Sayı: 3

Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration

Yeni Tanı Almış Neovasküler Tip Yaşa Bağlı Maküla Dejeneresanslı Gözlerde Aflibercept Tedavisi ile Elde Edilen Sonuçlar ve Başlangıç Lezyon Özellikleri ile İlişkisi

Filiz AFRASHİ
Serhad NALÇACI
Mine BARIŞ
Pelin KIYAR
Jale MENTEŞ
Pages
161–168
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Both groups showed statistically significant improvement in best-corrected visual acuity (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate functional and anatomical responses to intravitreal aflibercept (IVA) treatment in newly diagnosed and untreated neovascular age-related macular degeneration (nvAMD) cases and to investigate the effect of baseline lesion characteristics on anatomical responses.
📊
Key Findings & Data:Materials and Methods: This prospective, cross-sectional study included a series of 139 eyes of 133 patients that were diagnosed with active nvAMD and had not been treated.
💡
Conclusion & Impact:Both groups showed statistically significant improvement in best-corrected visual acuity (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate functional and anatomical responses to intravitreal aflibercept (IVA) treatment in newly diagnosed and untreated neovascular age-related macular degeneration (nvAMD) cases and to investigate the effect of baseline lesion characteristics on anatomical responses. Materials and Methods: This prospective, cross-sectional study included a series of 139 eyes of 133 patients that were diagnosed with active nvAMD and had not been treated. All eyes were subjected to complete ophthalmological examination, spectral-domain optical coherence tomography and fluorescein angiography, and 42 eyes also underwent indocyanine green angiography. IVA treatment was performed using a “treat and extend” regimen after 3 injections at 4-6 weeks intervals. Anatomical and functional responses at 4 weeks after the last injection were evaluated in eyes that completed 3 injections and the subgroup of eyes that completed 6 IVA injections. The effect of baseline lesion characteristics on IVA treatment results was also investigated. Results: All 139 eyes included in the study received 3 IVA injections (group 1) and 62 received 6 IVA injections. Both groups showed statistically significant improvement in best-corrected visual acuity (p

Özet

Amaç: Yeni tanı almış ve daha önce hiç tedavi uygulanmamış neovasküler tip yaşa bağlı maküla dejeneresanslı (nvYBMD) gözlerde intravitreal aflibercept (İVA) tedavisi ile elde edilen fonksiyonel ve anatomik sonuçları belirlemek, başlangıç lezyon özelliklerinin tedavi sonuçları üzerine etkisini araştırmak. Gereç ve Yöntem: Bu kesitsel, prospektif klinik çalışmaya aktif nvYBMD tanısı konulan, tedavi almamış 133 hastanın 139 gözü dahil edilmiştir. Gözlerin hepsinde tam oftalmolojik muayene, spektral-domain optik koherens tomografi ve floressein anjiyografi tetkikleri yapılmış olup 42 göze ayrıca indosiyanin yeşili anjiyografi çekilmiştir. İVA tedavisi, 4-6 hafta ara ile ardışık yapılan 3 doz tedaviyi takiben “tedavi et ve uzat” rejimine göre sürdürülmüştür. Üç doz tedaviyi tamamlayan gözler ile bu gözler arasından düzenli takip ve tedavisi yapılarak 6 doz tedaviyi tamamlayan gözlerde, son tedaviden 1 ay sonra yapılan kontrol muayenesindeki anatomik ve fonksiyonel cevaplar kesitsel olarak incelenmiştir. Tedavi sonuçları ile başlangıç lezyon özelliklerinin sonuçlar üzerine olan etkileri analiz edilmiştir. Bulgular: Çalışmaya dahil edilen ve 3 doz İVA tedavisi alan 139 göz (grup 1) ile bunlar arasından 6 doz İVA tedaviyi tamamlayabilen 62 gözün (grup 2) tedavi öncesi ortalama EİDGK’lerinin tedavi ile istatistiksel olarak anlamlı artış gösterdiği saptanmıştır (sırasıyla; p

🔖

Cite This Article

AFRASHİ, F., NALÇACI, S., BARIŞ, M., KIYAR, P., MENTEŞ, J. (2022). Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration. Türk Oftalmoloji Dergisi, Cilt: 51 - Sayı: 3, 161–168. https://ajindex.com/articles/637629

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Stewart MW. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Rev Clin Pharmacol. 2013;6:103-113.
  2. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548.
  3. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193-201.
  4. Saito M, Kano M, Itagaki K, Sekiryu T. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration. Jpn J Ophthalmol. 2017;61:74-83.
  5. DeCroos FC, Reed D, Adam MK, Salz D, Gupta OP, Ho AC, Regillo CD. Treat and extend therapy using aflibercept for neovascular age-related macular degeneration: A prospective clinical trial. Am J Ophthalmol. 2017;180:142-150.
  6. Yamamoto A, Okada AA, Nakayama M, Yoshida Y, Kobayashi H. One-year outcomes of a treat-and-extend regimen of aflibercept for exudative age-related macular degeneration. Ophthalmologica. 2017;237:139-144.
  7. Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, Morlet N, Hunyor AP, Essex RW, Arnold JJ, Gillies MC; Fight Retinal Blindness Study Group. Two year outcomes of treat and extend intravitreal therapy using aflibercept preferentially for neovascular age related macular degeneration. Retina. 2018;38:20-28.
  8. Kikushima W, Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kume A, Mabuchi F, Iijima H. Incidence and risk factors of retreatment after three monthly aflibercept therapy for exudative age-related macular degeneration. Sci Rep. 2017;7:44020. Minami S, Nagai N, Suzuki M, Kurihara T, Sonobe H, Kamoshita M, Uchida A, Shinoda H, Takagi H, Sonoda S, Sakamoto T, Tsubota K, Ozawa Y. Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline. Sci Rep. 2018;8:58. 10. Miyamoto N, Mandai M, Kojima H, Kameda T, Shimozono M, Nishida A, Kurimoto Y. Response of eyes with age-